TITLE:
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

CONDITION:
Locally Advanced Breast Cancer

INTERVENTION:
Fulvestrant

SUMMARY:

      The purpose of this study is to compare the efficacy of Faslodex (fulvestrant) to Aromasin
      (exemestane) in hormone receptor positive postmenopausal women with advanced breast cancer.
      Patients will be treated until disease progression or until the investigator has determined
      that treatment is not in the best interest of the patient, whichever occurs first.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 32 Years to 91 Years
Criteria:

        Inclusion Criteria:

          -  Biopsy confirmation of Breast Cancer

          -  Breast Cancer has continued to grow after having received treatment with an aromatase
             inhibitor

          -  Postmenopausal women defined as a women who has stopped having menstrual periods

          -  Evidence of hormone sensitivity

          -  Written informed consent to participate in the trial

        Exclusion Criteria:

          -  Previous treatment with Faslodex (fulvestrant) or Aromasin (exemestane)

          -  Any hormonal therapy used to modify the course of an additional medical condition
             after prior treatment with a non-steroidal aromatase inhibitor

          -  Treatment with an investigational or non-approved drug within one month

          -  An existing serious disease, illness, or condition that will prevent participation or
             compliance with study procedures

          -  A history of allergies to any active or inactive ingredients of Faslodex or
             Exemestane (i.e. castor oil or Mannitol)
      
